{"id":"W3028188420","doi":"10.1016/j.jval.2020.04.1534","title":"PCN28 CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS (CDK4/6I) IN HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED/METASTATIC BREAST CANCER (A/MBC): A SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Palbociclib; Letrozole; Medicine; Fulvestrant; Metastatic breast cancer; Internal medicine; Oncology; Progression-free survival; Cyclin-dependent kinase 4; Cancer; Breast cancer; Aromatase; Gynecology; Estrogen receptor; Overall survival; Cyclin-dependent kinase 2; Cell cycle","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006614281,0.0008633951,0.00555226,0.003565771,0.0003597708,0.00174337,0.001210396,0.001233791,0.003675637],"category_scores_gemma":[0.02127405,0.0006354183,0.00790758,0.004275309,0.0007844716,0.001203436,0.001129286,0.001254394,0.0001973383],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001725408,"about_ca_system_score_gemma":0.003788496,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006026877,"about_ca_topic_score_gemma":0.02136976,"domain_scores_codex":[0.9959288,0.00147493,0.001428223,0.0004275155,0.000573814,0.0001667342],"domain_scores_gemma":[0.9876255,0.008818574,0.002500489,0.0001908981,0.0007006529,0.0001638488],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.002235915,0.00005221339,0.003068405,0.8806521,0.05123688,0.00008128822,0.0001460807,0.0001813077,0.0003476044,0.00026765,0.001224087,0.06050646],"study_design_scores_gemma":[0.003159885,0.0008190743,0.0168233,0.4621878,0.4958819,0.0003394669,0.0003562901,0.0001725065,0.0004412106,0.0007231515,0.01902853,0.00006699299],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00313537,0.9956387,0.0000854978,0.0001951129,0.00006288342,0.0001416716,0.000441499,0.000004692528,0.0002946712],"genre_scores_gemma":[0.06870677,0.9290503,0.0007094919,0.0007408909,0.00007795235,0.0002607621,0.0003380361,0.000005166139,0.0001107208],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.006614281,"threshold_uncertainty_score":0.03498012,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06409227364805688,"score_gpt":0.3774474890229369,"score_spread":0.31335521537488,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}